Logo image of EW

EDWARDS LIFESCIENCES CORP (EW) Stock Fundamental Analysis

USA - NYSE:EW - US28176E1082 - Common Stock

75.4 USD
+0.31 (+0.41%)
Last: 9/17/2025, 12:39:59 PM
Fundamental Rating

7

Overall EW gets a fundamental rating of 7 out of 10. We evaluated EW against 191 industry peers in the Health Care Equipment & Supplies industry. EW scores excellent points on both the profitability and health parts. This is a solid base for a good stock. EW has a correct valuation and a medium growth rate. These ratings could make EW a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

EW had positive earnings in the past year.
EW had a positive operating cash flow in the past year.
In the past 5 years EW has always been profitable.
EW had a positive operating cash flow in each of the past 5 years.
EW Yearly Net Income VS EBIT VS OCF VS FCFEW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

1.2 Ratios

EW has a better Return On Assets (30.75%) than 99.48% of its industry peers.
EW has a Return On Equity of 39.33%. This is amongst the best in the industry. EW outperforms 98.95% of its industry peers.
Looking at the Return On Invested Capital, with a value of 11.77%, EW belongs to the top of the industry, outperforming 92.67% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for EW is significantly above the industry average of 8.46%.
The last Return On Invested Capital (11.77%) for EW is well below the 3 year average (15.82%), which needs to be investigated, but indicates that EW had better years and this may not be a problem.
Industry RankSector Rank
ROA 30.75%
ROE 39.33%
ROIC 11.77%
ROA(3y)21.77%
ROA(5y)18.87%
ROE(3y)29.68%
ROE(5y)26.56%
ROIC(3y)15.82%
ROIC(5y)17.27%
EW Yearly ROA, ROE, ROICEW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

EW's Profit Margin of 72.96% is amongst the best of the industry. EW outperforms 98.43% of its industry peers.
In the last couple of years the Profit Margin of EW has grown nicely.
The Operating Margin of EW (27.94%) is better than 94.76% of its industry peers.
In the last couple of years the Operating Margin of EW has remained more or less at the same level.
EW has a better Gross Margin (78.87%) than 91.62% of its industry peers.
In the last couple of years the Gross Margin of EW has remained more or less at the same level.
Industry RankSector Rank
OM 27.94%
PM (TTM) 72.96%
GM 78.87%
OM growth 3Y-5.94%
OM growth 5Y-1.04%
PM growth 3Y38.76%
PM growth 5Y26.09%
GM growth 3Y1.43%
GM growth 5Y1.33%
EW Yearly Profit, Operating, Gross MarginsEW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EW is creating value.
EW has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, EW has less shares outstanding
The debt/assets ratio for EW has been reduced compared to a year ago.
EW Yearly Shares OutstandingEW Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
EW Yearly Total Debt VS Total AssetsEW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

An Altman-Z score of 11.70 indicates that EW is not in any danger for bankruptcy at the moment.
The Altman-Z score of EW (11.70) is better than 91.62% of its industry peers.
The Debt to FCF ratio of EW is 1.03, which is an excellent value as it means it would take EW, only 1.03 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.03, EW belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
A Debt/Equity ratio of 0.06 indicates that EW is not too dependend on debt financing.
EW has a better Debt to Equity ratio (0.06) than 65.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 1.03
Altman-Z 11.7
ROIC/WACC1.37
WACC8.61%
EW Yearly LT Debt VS Equity VS FCFEW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

EW has a Current Ratio of 4.68. This indicates that EW is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.68, EW is doing good in the industry, outperforming 73.30% of the companies in the same industry.
A Quick Ratio of 3.87 indicates that EW has no problem at all paying its short term obligations.
The Quick ratio of EW (3.87) is better than 72.25% of its industry peers.
Industry RankSector Rank
Current Ratio 4.68
Quick Ratio 3.87
EW Yearly Current Assets VS Current LiabilitesEW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for EW have decreased by -0.77% in the last year.
EW shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.13% yearly.
Looking at the last year, EW shows a decrease in Revenue. The Revenue has decreased by -1.09% in the last year.
The Revenue has been growing slightly by 4.58% on average over the past years.
EPS 1Y (TTM)-0.77%
EPS 3Y5.52%
EPS 5Y7.13%
EPS Q2Q%-4.29%
Revenue 1Y (TTM)-1.09%
Revenue growth 3Y1.3%
Revenue growth 5Y4.58%
Sales Q2Q%-6.13%

3.2 Future

Based on estimates for the next years, EW will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.37% on average per year.
EW is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.44% yearly.
EPS Next Y-1.88%
EPS Next 2Y4.69%
EPS Next 3Y7.22%
EPS Next 5Y9.37%
Revenue Next Year3.65%
Revenue Next 2Y6.66%
Revenue Next 3Y7.84%
Revenue Next 5Y8.44%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EW Yearly Revenue VS EstimatesEW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B 8B
EW Yearly EPS VS EstimatesEW Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

EW is valuated quite expensively with a Price/Earnings ratio of 29.34.
Compared to the rest of the industry, the Price/Earnings ratio of EW indicates a somewhat cheap valuation: EW is cheaper than 73.82% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.20. EW is around the same levels.
Based on the Price/Forward Earnings ratio of 26.26, the valuation of EW can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EW indicates a somewhat cheap valuation: EW is cheaper than 73.30% of the companies listed in the same industry.
EW's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.71.
Industry RankSector Rank
PE 29.34
Fwd PE 26.26
EW Price Earnings VS Forward Price EarningsEW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EW is valued a bit cheaper than the industry average as 73.30% of the companies are valued more expensively.
71.73% of the companies in the same industry are more expensive than EW, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 76.6
EV/EBITDA 22.89
EW Per share dataEW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

EW has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)4.11
EPS Next 2Y4.69%
EPS Next 3Y7.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EW!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EDWARDS LIFESCIENCES CORP

NYSE:EW (9/17/2025, 12:39:59 PM)

75.4

+0.31 (+0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-24 2025-07-24/amc
Earnings (Next)10-22 2025-10-22/amc
Inst Owners88.93%
Inst Owner Change-1.06%
Ins Owners0.16%
Ins Owner Change4.29%
Market Cap44.27B
Analysts76.28
Price Target90.17 (19.59%)
Short Float %1.78%
Short Ratio2.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.25%
Min EPS beat(2)4.11%
Max EPS beat(2)4.4%
EPS beat(4)4
Avg EPS beat(4)3.37%
Min EPS beat(4)1.57%
Max EPS beat(4)4.4%
EPS beat(8)4
Avg EPS beat(8)0.66%
EPS beat(12)5
Avg EPS beat(12)0.01%
EPS beat(16)6
Avg EPS beat(16)-0.9%
Revenue beat(2)0
Avg Revenue beat(2)-1.11%
Min Revenue beat(2)-2.1%
Max Revenue beat(2)-0.12%
Revenue beat(4)0
Avg Revenue beat(4)-4.22%
Min Revenue beat(4)-13.79%
Max Revenue beat(4)-0.12%
Revenue beat(8)0
Avg Revenue beat(8)-3.15%
Revenue beat(12)1
Avg Revenue beat(12)-2.51%
Revenue beat(16)1
Avg Revenue beat(16)-2.76%
PT rev (1m)0.49%
PT rev (3m)8.96%
EPS NQ rev (1m)0.23%
EPS NQ rev (3m)-3.42%
EPS NY rev (1m)0.56%
EPS NY rev (3m)0.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.08%
Revenue NY rev (1m)0.23%
Revenue NY rev (3m)1.27%
Valuation
Industry RankSector Rank
PE 29.34
Fwd PE 26.26
P/S 7.79
P/FCF 76.6
P/OCF 55.69
P/B 4.2
P/tB 5.83
EV/EBITDA 22.89
EPS(TTM)2.57
EY3.41%
EPS(NY)2.87
Fwd EY3.81%
FCF(TTM)0.98
FCFY1.31%
OCF(TTM)1.35
OCFY1.8%
SpS9.68
BVpS17.96
TBVpS12.94
PEG (NY)N/A
PEG (5Y)4.11
Profitability
Industry RankSector Rank
ROA 30.75%
ROE 39.33%
ROCE 13.14%
ROIC 11.77%
ROICexc 17.73%
ROICexgc 28.04%
OM 27.94%
PM (TTM) 72.96%
GM 78.87%
FCFM 10.17%
ROA(3y)21.77%
ROA(5y)18.87%
ROE(3y)29.68%
ROE(5y)26.56%
ROIC(3y)15.82%
ROIC(5y)17.27%
ROICexc(3y)20.51%
ROICexc(5y)22.13%
ROICexgc(3y)29.09%
ROICexgc(5y)31.03%
ROCE(3y)17.66%
ROCE(5y)19.29%
ROICexcg growth 3Y-5.47%
ROICexcg growth 5Y-8.01%
ROICexc growth 3Y-11.82%
ROICexc growth 5Y-8.6%
OM growth 3Y-5.94%
OM growth 5Y-1.04%
PM growth 3Y38.76%
PM growth 5Y26.09%
GM growth 3Y1.43%
GM growth 5Y1.33%
F-Score7
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 1.03
Debt/EBITDA 0.34
Cap/Depr 142.95%
Cap/Sales 3.82%
Interest Coverage 250
Cash Conversion 45.68%
Profit Quality 13.93%
Current Ratio 4.68
Quick Ratio 3.87
Altman-Z 11.7
F-Score7
WACC8.61%
ROIC/WACC1.37
Cap/Depr(3y)185.14%
Cap/Depr(5y)236.01%
Cap/Sales(3y)5.48%
Cap/Sales(5y)6.41%
Profit Quality(3y)37.92%
Profit Quality(5y)57.13%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.77%
EPS 3Y5.52%
EPS 5Y7.13%
EPS Q2Q%-4.29%
EPS Next Y-1.88%
EPS Next 2Y4.69%
EPS Next 3Y7.22%
EPS Next 5Y9.37%
Revenue 1Y (TTM)-1.09%
Revenue growth 3Y1.3%
Revenue growth 5Y4.58%
Sales Q2Q%-6.13%
Revenue Next Year3.65%
Revenue Next 2Y6.66%
Revenue Next 3Y7.84%
Revenue Next 5Y8.44%
EBIT growth 1Y0.21%
EBIT growth 3Y-4.72%
EBIT growth 5Y3.49%
EBIT Next Year10.05%
EBIT Next 3Y11.53%
EBIT Next 5Y12.05%
FCF growth 1Y-15.26%
FCF growth 3Y-42.99%
FCF growth 5Y-22.01%
OCF growth 1Y-15.47%
OCF growth 3Y-32.1%
OCF growth 5Y-14.39%